Pharmacology of bismuth-containing compounds

Area of Science:

• Pharmacology
• Gastroenterology
• Toxicology

Background:

• Bismuth compounds possess a long history of medicinal use spanning over 200 years.
• Recent therapeutic applications have spurred renewed scientific interest in bismuth agents.
• Colloidal bismuth subcitrate and bismuth subsalicylate are two prominent examples of commonly utilized bismuth compounds.

Purpose of the Study:

• To review the mechanisms of action, pharmacokinetic properties, and toxicity profiles of colloidal bismuth subcitrate and bismuth subsalicylate.
• To evaluate the safety and efficacy of bismuth compounds in the context of modern medical applications.
• To provide a scientific reevaluation of bismuth agents based on current research and usage patterns.

Main Methods:

• Literature review of existing scientific data on bismuth compounds.
• Analysis of pharmacokinetics and toxicity studies.
• Examination of clinical evidence for Helicobacter pylori eradication and traveler's diarrhea prevention.

Main Results:

• Bismuth compounds exhibit well-defined modes of action relevant to gastrointestinal infections.
• Pharmacokinetic data suggest limited systemic absorption and accumulation under therapeutic conditions.
• Bismuth toxicity in humans is improbable with appropriate dosing and treatment duration for indicated conditions.

Conclusions:

• Colloidal bismuth subcitrate and bismuth subsalicylate demonstrate favorable safety profiles for therapeutic use.
• These bismuth agents are effective in eradicating Helicobacter pylori infections.
• Bismuth compounds serve as a valuable option for the prevention of travelers' diarrhea.